HomeAI · summaries
Storia in 16 fonti
GSK rachète Nuvalent pour plus de 10 milliards de dollars
GSK va racheter l'américain Nuvalent pour 10,6 milliards de dollars. L’opération, qui devrait être officialisée au troisième trimestre, offre une prime de 40% par rapport aux près de 7 milliards de dollars de valorisation boursière de la biotech.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
mediapart.fr
Cancer: GSK annonce le rachat de l’américain Nuvalent pour 10,6 milliards de dollars
Le géant pharmaceutique britannique GSK a annoncé mardi un accord pour acquérir la société biopharmaceutique américaine Nuvalent, spécialisée dans le développement de thérapies…
- ·
cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
- ·
lecho.be
GSK en pourparlers pour racheter Nuvalent pour plus de 9 milliards de dollars
GSK serait en discussions avancées pour racheter la biotech Nuvalent pour 9 à 10 milliards de dollars, selon le Financial Times. L’opération, qui pourrait être conclue dès cette…
- ·
handelsblatt.com
Nuvalent: GSK übernimmt Krebsspezialisten für 10,6 Milliarden Dollar
Der britische Pharmariese will mit der Übernahme des US-Biotechs sein Onkologie-Portfolio ausbauen. Es wäre ein früher Erfolg des neuen Konzernchefs Miels.
- ·
thehindubusinessline.com
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.
- ·
cityam.com
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.
- ·
endpoints.news
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
- ·
statnews.com
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
- ·
independent.co.uk
GSK to buy US lung cancer drug specialist Nuvalent for £8bn
The acquisition is thought to be GSK’s biggest deal in more than a decade.
- ·
GSK rachète Nuvalent pour plus de 10 milliards de dollars
GSK va racheter l'américain Nuvalent pour 10,6 milliards de dollars. L’opération, qui devrait être officialisée au troisième trimestre, offre une prime de 40% par rapport aux près…
- ·
hindustantimes.com
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. | Business News
- ·
ilsole24ore.com
Gsk sotto pressione a Londra, pesa l'accordo per l'acquisto di Nuvalent
Operazione da 10,6 mld di dollari con il lancio di un'Opa
- ·
benzinga.com
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
- ·
valor.globo.com
GSK compra Nuvalent por US$ 10,6 bilhões e amplia aposta em oncologia
A aquisição deve dar à GSK a propriedade de três medicamentos candidatos para o tratamento de câncer de pulmão
- ·
newsbytesapp.com
GSK buys US biopharma company Nuvalent for $10.6B
Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.
- ·
nrc.nl
VS zetten onder meer BYD en Alibaba op zwarte lijst vanwege vermeende link met Chinees leger
Welkom in dit liveblog! De economieredactie van NRC houdt je hier de hele week op de hoogte van het belangrijkste economische en financiële nieuws.
- ·
malaymail.com
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent
Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands lung...